Diabetes Mellitus, Type 2
Conditions
Keywords
Cholecystokinin, ultrasonography, Albiglutide, Gallbladder ejection fraction
Brief summary
Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus. The primary objective of this study is to assess if a single dose of albiglutide can affect cholecystokinin-induced gallbladder emptying. To make this assessment, each study participant will receive a dose of albiglutide and a dose of placebo followed by cholecystokinin (CCK) infusion and ultrasound measurement of the gallbladder. The study will be comprised of two periods and 20 subjects. The screening visit will occur within 42 days of the start of Treatment Period 1. The Treatment Periods will be separated by a washout period of a minimum of 42 days. Subjects will return for a follow-up visit after 28 days following the last dose of albiglutide or placebo. The total duration of a subject's participation from Screening to Follow-up will be approximately 17.5 weeks. This study is a post marketing commitment to the United States Food and Drug Administration (USFDA).
Interventions
Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
DRUGPlacebo
Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
DRUGCCK (Kinevac)
CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Between 18 and 65 years of age * Healthy * Have venous access sufficient to allow for intravenous (IV) infusion and blood sampling as per protocol * Subject's body mass index (BMI) is \>=18 kilogram (kg)/meter(m)\^2 and \<=30 kg/m\^2 * Male or * Female: if she is not pregnant (as confirmed by a test at screening and at other timepoints), not lactating, and at least one of the following conditions applies: a) cannot bear children OR b) agrees to follow contraception requirements defined in the protocol * Capable of giving signed informed consent
Exclusion criteria
* Alanine aminotransferase (ALT) \>1.5x Upper limit of normal (ULN) * Bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%) * Current or chronic history of liver disease, or known hepatic or biliary abnormalities * QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 milliseconds (msec) * Systolic blood pressure is \>=140 millimetre (mm) mercury (Hg) at Screening * Diastolic blood pressure is \>=90 mm Hg at Screening * Heart rate is \>100 beats/min at Screening * Fasting triglyceride level \>300 milligram/decilitre at Screening * History of cholecystitis or other gallbladder disease * History of gallstones, biliary motility dysfunction, or any condition rendering the subject unsuitable for ultrasonography assessments * Prior cholecystectomy or any other gallbladder or biliary ducts procedure, prior ileal or gastric surgery, or any other medical procedure that precluded gallbladder emptying * History of significant cardiovascular or pulmonary dysfunction prior to screening * History of thyroid dysfunction * History of intestinal obstruction, ileus, lap-band, gastrointestinal surgery or any other procedures that in the opinion of the investigator could influence gastric emptying (e.g., gastrectomy, gastric bypass) * History of acute or chronic pancreatitis * History of abdominal pain of unknown cause * History of severe gastrointestinal disease, including gastroparesis, inflammatory bowel disease, Crohn's disease, or irritable bowel syndrome * Personal or family history of multiple endocrine neoplasia type 2 * Personal or family history of medullary carcinoma of the thyroid * Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days * Current or past use of medications that may have significantly affected gastrointestinal and/or gallbladder motility or pancreatic or hepatobiliary systems * History of regular alcohol consumption within 6 months of the study * Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products within 3 months prior to screening * Subject has a history of significant weight loss or is currently attempting weight loss * History of sensitivity or contraindication to any of the study medications or components thereof or a history of drug or other allergy * Subject has previously received any GLP-1 mimetic compound (e.g., exenatide, liraglutide, lixisenatide, dulaglutide) * A biliary pathology as assessed by ultrasound * An abnormal (i.e., outside the normal reference range) thyroid function test assessed by thyroid stimulating hormone at screening * An abnormal amylase or lipase test at screening * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result * A positive pre-study drug/alcohol screen * A positive test for Human immunodeficiency virus (HIV) antibody * A screening ultrasound which demonstrates inadequate imaging of gallbladder, main pancreatic duct, or common duct * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56-day period * The subject participated in a clinical trial and received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) * Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion | Day 4 in each treatment period | Common bile duct ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Baseline is the average of the three diameter assessments at -15, -10, and -5 minutes relative to start of CCK infusion on Day 4. Change from Baseline was calculated as the value at the indicated time point minus the Baseline value. Adjusted mean and its standard error have been presented. |
| Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK Infusion | Day 4 in each treatment period | Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). |
| Maximum Gallbladder Ejection Fraction Value During CCK Infusion | Day 1 and Day 4 in each treatment period | Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). |
| Area Under the Effect Curve for Gallbladder Volume (AUEC VL) | Day 4 in each treatment period | Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Adjusted mean and its standard error is presented. |
| Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum Effect | Day 4 in each treatment period | Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Baseline gallbladder volume is the average of the 3 gallbladder volume measurements prior to CCK infusion on Day 4, for each treatment period. Adjusted mean and its standard error are presented. |
| Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK Infusion | Day 4 in each treatment period | Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). |
| Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK Infusion | Day 4 in each treatment period | Pancreatic duct ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Baseline is the average of the three diameter assessments at -15, -10, and -5 minutes relative to start of CCK infusion on Day 4. Change from Baseline was calculated as the value at the indicated time point minus the Baseline value. Adjusted mean and its standard error are presented. Baseline was calculated as the value at the indicated time point minus the Baseline value. Only those participants available at the indicated time points were analyzed. |
| Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum Effect | Day 4 in each treatment period | Gallbladder ejection fraction (EF) is defined as the reduction in gallbladder volume at any time point from Baseline divided by baseline gallbladder volume and multiplied by 100. Baseline gallbladder volume is the average of the 3 gallbladder volume measurements prior to CCK infusion on Day 4, for each treatment period. Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Adjusted mean and its standard error have been presented. |
| Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF) | Day 4 in each treatment period | Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Adjusted mean and its standard error have been presented. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Heart Rate | Day -1, Baseline Day 1(Pre-dose), Day 2, Day 3, and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4 in each treatment period and Follow-up (a total of approximately 12 weeks) | Baseline is defined as Day 1 (pre-dose) visit. Heart rate was measured in a semi-supine position after 5 minutes of rest, at each indicated time point. Assessments were performed on Day -1, Day 2, Day 3 and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the indicated time points (represented by n=X,X in the category titles) were analyzed. |
| Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance | Day -1 in each treatment period and Follow-up (at approximately Week 12) | The following parameters were measured through blood sampling. Hematology: Hematocrit, Hemoglobin, Lymphocytes, Neutrophil Count, Platelet Count, While Blood Cell Count (WBC); Clinical Chemistry: Albumin, Calcium, Creatinine, Glucose, Magnesium, Phosphorus, Potassium, Sodium, Total carbon dioxide; Liver Function Tests: Alanine transaminase (ALT), Aspartate transaminase, Alkaline Phosphatase, Total Bilirubin, Total Bilirubin + ALT. Values were considered to be of potential clinical importance if they had a 'low' or 'high' flag with respect to a pre-defined clinical concern range. Only participants starting each period (represented by n=X) with a particular treatment were analyzed. The follow-up time point is not restricted to a treatment or treatment period. |
| Change From Baseline in Electrocardiogram (ECG) Parameters | Baseline (Day -1) and Day 4 in each treatment period, and at Follow-up (at approximately Week 12) | Single 12-lead ECG was obtained in a semi-supine position after 5 minutes of rest at each indicated time point using an ECG machine that automatically calculated the heart rate and measured the PR, QRS, QT, and QT corrected by Fridericia's formula (QTcF) intervals. Change from Baseline was calculated as value at indicated time point minus Baseline value. |
| Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event | From Day -1 in treatment period 1 and up to Follow-up Visit (a total of approximately 12 weeks) | An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase \>=3 x upper limit of normal (ULN), and total bilirubin \>=2 x ULN or international normalised ratio \>1.5. AEs were classified as potentially drug-related, based on the investigator's judgement. Refer to the general AE/SAE module for a list of AEs and SAEs. |
| Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Day -1 and Follow-up (assessed up to a total of approximately 12 weeks) | Urine dipstick test was carried out on Day -1 and at Follow-up. Urinalysis parameters assessed were glucose, ketones, nitrite and protein. Dipstick results were categorized as Normal (glucose), Negative or Trace (ketones), and Negative (nitrite and protein). Only participants available at the indicated time points (as represented by n=X, X, X in the category titles) were analyzed. The resultant fields with no available data have been represented by 'NA'. |
| Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | Day -1, Baseline Day 1(Pre-dose), Day 2, Day 3, and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4 in each treatment period and Follow-up (assessed up to a total of approximately 12 weeks) | Baseline is defined as Day 1 (pre-dose) visit. SBP and DBP were measured in a semi-supine position after 5 minutes of rest, at each indicated time point. Assessments were performed on Day -1, Day 1 (pre-dose), Day 2, Day 3 and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the indicated time points (represented by n=X,X in the category titles) were analyzed. |
Countries
United States
Participant flow
Pre-assignment details
Eligible participants were randomized to one of the two treatments in Treatment Period 1 followed by a wash-out period and crossed over to other treatment in Treatment Period 2.
Participants by arm
| Arm | Count |
|---|---|
| Albiglutide 50 mg and Placebo In a total of two treatment periods, participants received Albiglutide 50 mg (A) and Placebo (P) (in a sequence of either A-P or P-A), each administered subcutaneously as a single dose, using a fully disposable pen injector system. Participants also received an intravenous infusion of cholecystokinin (sincalide) in each period. | 20 |
| Total | 20 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Treatment Period 2 - 4 Days | Adverse Event | 0 | 1 |
| Treatment Period 2 - 4 Days | Physician Decision | 1 | 0 |
| Treatment Period 2 - 4 Days | Protocol Violation | 1 | 0 |
Baseline characteristics
| Characteristic | Albiglutide 50 mg and Placebo |
|---|---|
| Age, Continuous | 35.8 Years STANDARD_DEVIATION 9.33 |
| Race/Ethnicity, Customized African American/African Heritage | 15 Participants |
| Race/Ethnicity, Customized White - White/Caucasian/European Heritage | 5 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 8 / 18 | 9 / 20 |
| serious Total, serious adverse events | 0 / 18 | 0 / 20 |
Outcome results
Primary
Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF)
Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Adjusted mean and its standard error have been presented.
Time frame: Day 4 in each treatment period
Population: Evaluable Subjects
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF) | 1004.2510 %*min | Standard Error 247.34751 |
| Albiglutide 50 mg | Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF) | 458.2926 %*min | Standard Error 247.34751 |
p-value: 0.129195% CI: [-1260, 168.0858]Mixed Models Analysis
Primary
Area Under the Effect Curve for Gallbladder Volume (AUEC VL)
Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Adjusted mean and its standard error is presented.
Time frame: Day 4 in each treatment period
Population: Evaluable Subjects
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Area Under the Effect Curve for Gallbladder Volume (AUEC VL) | 610.5642 mL*min | Standard Error 91.00301 |
| Albiglutide 50 mg | Area Under the Effect Curve for Gallbladder Volume (AUEC VL) | 863.1741 mL*min | Standard Error 91.00301 |
p-value: 0.029195% CI: [29.5081, 475.7117]Mixed Models Analysis
Primary
Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum Effect
Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Baseline gallbladder volume is the average of the 3 gallbladder volume measurements prior to CCK infusion on Day 4, for each treatment period. Adjusted mean and its standard error are presented.
Time frame: Day 4 in each treatment period
Population: Evaluable Subjects
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum Effect | 8.8385 Millilitre (mL) | Standard Error 1.39713 |
| Albiglutide 50 mg | Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum Effect | 8.4637 Millilitre (mL) | Standard Error 1.39713 |
p-value: 0.796195% CI: [-3.4109, 2.6614]Mixed Models Analysis
Primary
Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum Effect
Gallbladder ejection fraction (EF) is defined as the reduction in gallbladder volume at any time point from Baseline divided by baseline gallbladder volume and multiplied by 100. Baseline gallbladder volume is the average of the 3 gallbladder volume measurements prior to CCK infusion on Day 4, for each treatment period. Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Adjusted mean and its standard error have been presented.
Time frame: Day 4 in each treatment period
Population: Evaluable Subjects: Participants in the 'All Subjects' population who had gallbladder ultrasonography assessment pre-treatment and post-Baseline (during CCK infusion) for both periods. 'All Subjects' population comprised participants who received at least one dose of Investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum Effect | 47.4352 Percent of gallbladder EF | Standard Error 4.00997 |
| Albiglutide 50 mg | Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum Effect | 38.4331 Percent of gallbladder EF | Standard Error 4.00997 |
p-value: 0.122995% CI: [-20.5781, 2.5739]Mixed Models Analysis
Primary
Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion
Common bile duct ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Baseline is the average of the three diameter assessments at -15, -10, and -5 minutes relative to start of CCK infusion on Day 4. Change from Baseline was calculated as the value at the indicated time point minus the Baseline value. Adjusted mean and its standard error have been presented.
Time frame: Day 4 in each treatment period
Population: Evaluable for Bile: Participants with Baseline and post-Baseline common bile duct diameter values for both periods
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion | 0.08814 Centimetre (cm) | Standard Error 0.008308 |
| Albiglutide 50 mg | Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion | 0.07358 Centimetre (cm) | Standard Error 0.008308 |
p-value: 0.073395% CI: [-0.030666, 0.001554]Mixed Models Analysis
Primary
Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK Infusion
Pancreatic duct ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion). Baseline is the average of the three diameter assessments at -15, -10, and -5 minutes relative to start of CCK infusion on Day 4. Change from Baseline was calculated as the value at the indicated time point minus the Baseline value. Adjusted mean and its standard error are presented. Baseline was calculated as the value at the indicated time point minus the Baseline value. Only those participants available at the indicated time points were analyzed.
Time frame: Day 4 in each treatment period
Population: Evaluable for Pancreatic: Participants with Baseline and post-Baseline pancreatic duct diameter values for both periods
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK Infusion | 0.04359 Centimetre (CM) | Standard Error 0.01373 |
| Albiglutide 50 mg | Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK Infusion | 0.04511 Centimetre (CM) | Standard Error 0.01471 |
p-value: 0.942495% CI: [-0.045665, 0.048717]Mixed Models Analysis
Primary
Maximum Gallbladder Ejection Fraction Value During CCK Infusion
Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion).
Time frame: Day 1 and Day 4 in each treatment period
Population: Evaluable Subjects
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Maximum Gallbladder Ejection Fraction Value During CCK Infusion | 44.5989 Percentage | Standard Error 5.11879 |
| Albiglutide 50 mg | Maximum Gallbladder Ejection Fraction Value During CCK Infusion | 28.2997 Percentage | Standard Error 5.11879 |
p-value: 0.031795% CI: [-31.0762, -1.5223]Mixed Models Analysis
Primary
Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK Infusion
Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion).
Time frame: Day 4 in each treatment period
Population: Evaluable Subjects
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK Infusion | 37.64706 Minutes | Standard Deviation 13.1241 |
| Albiglutide 50 mg | Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK Infusion | 32.94118 Minutes | Standard Deviation 14.5836 |
Primary
Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK Infusion
Gallbladder ultrasonography was done at Day 1 (-15, -10, and -5 minutes \[min\] relative to start of albiglutide/placebo injection) and Day 4 (\[prior to CCK infusion\] -15, -10, -5 min, followed by \[during CCK infusion\] every 5 min between 0 and 50 min, then \[after CCK infusion\] at 60, 70, and 80 min, relative to the start of CCK infusion).
Time frame: Day 4 in each treatment period
Population: Evaluable Subjects
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK Infusion | 37.64706 Minutes | Standard Deviation 13.1241 |
| Albiglutide 50 mg | Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK Infusion | 32.94118 Minutes | Standard Deviation 14.5836 |
Secondary
Change From Baseline in Electrocardiogram (ECG) Parameters
Single 12-lead ECG was obtained in a semi-supine position after 5 minutes of rest at each indicated time point using an ECG machine that automatically calculated the heart rate and measured the PR, QRS, QT, and QT corrected by Fridericia's formula (QTcF) intervals. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Time frame: Baseline (Day -1) and Day 4 in each treatment period, and at Follow-up (at approximately Week 12)
Population: All Subjects
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Electrocardiogram (ECG) Parameters | QTcF | -7.7 Milliseconds (msec) | Standard Deviation 12.33 |
| Placebo | Change From Baseline in Electrocardiogram (ECG) Parameters | PR | 2.1 Milliseconds (msec) | Standard Deviation 8.58 |
| Placebo | Change From Baseline in Electrocardiogram (ECG) Parameters | QRS | -1.8 Milliseconds (msec) | Standard Deviation 6.82 |
| Placebo | Change From Baseline in Electrocardiogram (ECG) Parameters | QT | -5.0 Milliseconds (msec) | Standard Deviation 17.69 |
| Albiglutide 50 mg | Change From Baseline in Electrocardiogram (ECG) Parameters | QT | -19.9 Milliseconds (msec) | Standard Deviation 21.08 |
| Albiglutide 50 mg | Change From Baseline in Electrocardiogram (ECG) Parameters | QTcF | -7.0 Milliseconds (msec) | Standard Deviation 15.85 |
| Albiglutide 50 mg | Change From Baseline in Electrocardiogram (ECG) Parameters | QRS | -0.7 Milliseconds (msec) | Standard Deviation 4.46 |
| Albiglutide 50 mg | Change From Baseline in Electrocardiogram (ECG) Parameters | PR | 2.2 Milliseconds (msec) | Standard Deviation 5.76 |
Secondary
Change From Baseline in Heart Rate
Baseline is defined as Day 1 (pre-dose) visit. Heart rate was measured in a semi-supine position after 5 minutes of rest, at each indicated time point. Assessments were performed on Day -1, Day 2, Day 3 and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the indicated time points (represented by n=X,X in the category titles) were analyzed.
Time frame: Day -1, Baseline Day 1(Pre-dose), Day 2, Day 3, and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4 in each treatment period and Follow-up (a total of approximately 12 weeks)
Population: All Subjects
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Heart Rate | Period 1, Day 2, n=10, 10 | 2.4 Beats per minute (bpm) | Standard Deviation 2.67 |
| Placebo | Change From Baseline in Heart Rate | Period 2, Day 2, n=8, 10 | 2.5 Beats per minute (bpm) | Standard Deviation 7.91 |
| Placebo | Change From Baseline in Heart Rate | Period 1, Day 4 (-15 min), n=10, 10 | 3.8 Beats per minute (bpm) | Standard Deviation 9.15 |
| Placebo | Change From Baseline in Heart Rate | Period 2, Day 3, n=8, 10 | 3.4 Beats per minute (bpm) | Standard Deviation 6.05 |
| Placebo | Change From Baseline in Heart Rate | Period 1, Day 3, n=10, 10 | 4.7 Beats per minute (bpm) | Standard Deviation 6.72 |
| Placebo | Change From Baseline in Heart Rate | Period 2, Day 4 (-15 min), n=8, 10 | 1.0 Beats per minute (bpm) | Standard Deviation 2.78 |
| Placebo | Change From Baseline in Heart Rate | Period 2, Day 4 (80 min), n=8, 9 | 1.8 Beats per minute (bpm) | Standard Deviation 3.58 |
| Placebo | Change From Baseline in Heart Rate | Period 1, Day 4 (80 min), n=10, 10 | 1.4 Beats per minute (bpm) | Standard Deviation 5.5 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 2, Day 4 (80 min), n=8, 9 | 6.3 Beats per minute (bpm) | Standard Deviation 11.48 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 1, Day 2, n=10, 10 | 4.3 Beats per minute (bpm) | Standard Deviation 4.6 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 1, Day 3, n=10, 10 | 7.9 Beats per minute (bpm) | Standard Deviation 4.41 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 1, Day 4 (-15 min), n=10, 10 | 8.5 Beats per minute (bpm) | Standard Deviation 4.74 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 1, Day 4 (80 min), n=10, 10 | 9.4 Beats per minute (bpm) | Standard Deviation 7.59 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 2, Day 2, n=8, 10 | 4.2 Beats per minute (bpm) | Standard Deviation 6.18 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 2, Day 3, n=8, 10 | 9.4 Beats per minute (bpm) | Standard Deviation 8.19 |
| Albiglutide 50 mg | Change From Baseline in Heart Rate | Period 2, Day 4 (-15 min), n=8, 10 | 6.3 Beats per minute (bpm) | Standard Deviation 5.7 |
Secondary
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Baseline is defined as Day 1 (pre-dose) visit. SBP and DBP were measured in a semi-supine position after 5 minutes of rest, at each indicated time point. Assessments were performed on Day -1, Day 1 (pre-dose), Day 2, Day 3 and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the indicated time points (represented by n=X,X in the category titles) were analyzed.
Time frame: Day -1, Baseline Day 1(Pre-dose), Day 2, Day 3, and 15 minutes (-15 min) prior to dosing and 80 min post dosing on Day 4 in each treatment period and Follow-up (assessed up to a total of approximately 12 weeks)
Population: All Subjects
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 4 (-15 min), n=10, 10 | 6.3 Millimeters of mercury (mmHg) | Standard Deviation 8.26 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 4 (-15 min), n=10, 10 | 4.8 Millimeters of mercury (mmHg) | Standard Deviation 11.29 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 4 (-15 min), n=8, 10 | 3.3 Millimeters of mercury (mmHg) | Standard Deviation 5.23 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 4 (80 min), n=10, 10 | 2.2 Millimeters of mercury (mmHg) | Standard Deviation 8.53 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 2, n=8, 10 | -2.1 Millimeters of mercury (mmHg) | Standard Deviation 8.37 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 2, n=8, 10 | 2.1 Millimeters of mercury (mmHg) | Standard Deviation 9.7 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 4 (80 min), n=8, 9 | 6.4 Millimeters of mercury (mmHg) | Standard Deviation 6.3 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 3, n=8, 10 | -2.5 Millimeters of mercury (mmHg) | Standard Deviation 7.67 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 4 (80 min), n=10, 10 | 2.2 Millimeters of mercury (mmHg) | Standard Deviation 5.12 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 4 (-15 min), n=8, 10 | 4.5 Millimeters of mercury (mmHg) | Standard Deviation 9.15 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 2, n=10, 10 | 2.5 Millimeters of mercury (mmHg) | Standard Deviation 8.55 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 4 (80 min), n=8, 9 | 8.9 Millimeters of mercury (mmHg) | Standard Deviation 9.63 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 3, n=8, 10 | -3.4 Millimeters of mercury (mmHg) | Standard Deviation 8.09 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 2, n=10, 10 | 2.9 Millimeters of mercury (mmHg) | Standard Deviation 6.08 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 3, n=10, 10 | 4.2 Millimeters of mercury (mmHg) | Standard Deviation 6.86 |
| Placebo | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 3, n=10, 10 | 1.7 Millimeters of mercury (mmHg) | Standard Deviation 5.25 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 3, n=10, 10 | 4.3 Millimeters of mercury (mmHg) | Standard Deviation 8.79 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 4 (-15 min), n=10, 10 | 5.2 Millimeters of mercury (mmHg) | Standard Deviation 8.63 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 4 (80 min), n=10, 10 | 9.5 Millimeters of mercury (mmHg) | Standard Deviation 6.65 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 2, n=8, 10 | -4.3 Millimeters of mercury (mmHg) | Standard Deviation 7.12 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 3, n=8, 10 | -3.0 Millimeters of mercury (mmHg) | Standard Deviation 10.15 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 4 (-15 min), n=8, 10 | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 7.07 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 2, Day 4 (80 min), n=8, 9 | 0.4 Millimeters of mercury (mmHg) | Standard Deviation 7.62 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 2, n=10, 10 | 2.5 Millimeters of mercury (mmHg) | Standard Deviation 8.29 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 3, n=10, 10 | 3.2 Millimeters of mercury (mmHg) | Standard Deviation 9.61 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 4 (-15 min), n=10, 10 | 0.4 Millimeters of mercury (mmHg) | Standard Deviation 10.16 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 1, Day 4 (80 min), n=10, 10 | 9.4 Millimeters of mercury (mmHg) | Standard Deviation 7.23 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 2, n=8, 10 | 0.0 Millimeters of mercury (mmHg) | Standard Deviation 9.48 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 3, n=8, 10 | -0.4 Millimeters of mercury (mmHg) | Standard Deviation 8.63 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 4 (-15 min), n=8, 10 | 0.8 Millimeters of mercury (mmHg) | Standard Deviation 6.01 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | SBP, Period 2, Day 4 (80 min), n=8, 9 | 4.7 Millimeters of mercury (mmHg) | Standard Deviation 8.62 |
| Albiglutide 50 mg | Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | DBP, Period 1, Day 2, n=10, 10 | -0.4 Millimeters of mercury (mmHg) | Standard Deviation 9.22 |
Secondary
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick
Urine dipstick test was carried out on Day -1 and at Follow-up. Urinalysis parameters assessed were glucose, ketones, nitrite and protein. Dipstick results were categorized as Normal (glucose), Negative or Trace (ketones), and Negative (nitrite and protein). Only participants available at the indicated time points (as represented by n=X, X, X in the category titles) were analyzed. The resultant fields with no available data have been represented by 'NA'.
Time frame: Day -1 and Follow-up (assessed up to a total of approximately 12 weeks)
Population: All Subjects
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Nitrite Negative; Follow-up; n=0, 0, 19 | NA Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Trace; Day -1; n=18, 20, 0 | 0 Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Glucose Normal; Follow-up; n=0, 0, 19 | NA Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Nitrite Negative; Day -1; n=18, 20, 0 | 18 Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Negative; Follow-up; n=0, 0, 19 | NA Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Glucose Normal; Day -1; n=18, 20, 0 | 18 Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Protein Negative; Day -1; n=17, 20, 0 | 17 Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Negative; Day -1; n=18, 20, 0 | 18 Participants |
| Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Protein Negative; Follow-up; n=0, 0, 18 | NA Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Protein Negative; Follow-up; n=0, 0, 18 | NA Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Glucose Normal; Day -1; n=18, 20, 0 | 20 Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Glucose Normal; Follow-up; n=0, 0, 19 | NA Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Negative; Day -1; n=18, 20, 0 | 19 Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Trace; Day -1; n=18, 20, 0 | 1 Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Negative; Follow-up; n=0, 0, 19 | NA Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Nitrite Negative; Day -1; n=18, 20, 0 | 20 Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Nitrite Negative; Follow-up; n=0, 0, 19 | NA Participants |
| Albiglutide 50 mg | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Protein Negative; Day -1; n=17, 20, 0 | 20 Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Nitrite Negative; Day -1; n=18, 20, 0 | NA Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Negative; Day -1; n=18, 20, 0 | NA Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Glucose Normal; Day -1; n=18, 20, 0 | NA Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Nitrite Negative; Follow-up; n=0, 0, 19 | 19 Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Glucose Normal; Follow-up; n=0, 0, 19 | 19 Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Protein Negative; Follow-up; n=0, 0, 18 | 18 Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Negative; Follow-up; n=0, 0, 19 | 19 Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Ketones Trace; Day -1; n=18, 20, 0 | NA Participants |
| Albiglutide 50 mg and Placebo | Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick | Urine Protein Negative; Day -1; n=17, 20, 0 | NA Participants |
Secondary
Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance
The following parameters were measured through blood sampling. Hematology: Hematocrit, Hemoglobin, Lymphocytes, Neutrophil Count, Platelet Count, While Blood Cell Count (WBC); Clinical Chemistry: Albumin, Calcium, Creatinine, Glucose, Magnesium, Phosphorus, Potassium, Sodium, Total carbon dioxide; Liver Function Tests: Alanine transaminase (ALT), Aspartate transaminase, Alkaline Phosphatase, Total Bilirubin, Total Bilirubin + ALT. Values were considered to be of potential clinical importance if they had a 'low' or 'high' flag with respect to a pre-defined clinical concern range. Only participants starting each period (represented by n=X) with a particular treatment were analyzed. The follow-up time point is not restricted to a treatment or treatment period.
Time frame: Day -1 in each treatment period and Follow-up (at approximately Week 12)
Population: All Subjects
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance | Clinical Chemistry, Albiglutide Period 1, n=10 | 1 Participants |
| Placebo | Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance | Clinical Chemistry, Placebo Period 2, n=8 | 2 Participants |
| Placebo | Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance | Clinical Chemistry, Follow-up, n=17 | 1 Participants |
| Placebo | Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance | Hematology, Albiglutide Period 1, n=10 | 1 Participants |
| Placebo | Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance | Hematology, Albiglutide Period 2, n=10 | 1 Participants |
Secondary
Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase \>=3 x upper limit of normal (ULN), and total bilirubin \>=2 x ULN or international normalised ratio \>1.5. AEs were classified as potentially drug-related, based on the investigator's judgement. Refer to the general AE/SAE module for a list of AEs and SAEs.
Time frame: From Day -1 in treatment period 1 and up to Follow-up Visit (a total of approximately 12 weeks)
Population: All Subjects
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event | Any AE | 8 Participants |
| Placebo | Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event | Any SAE | 0 Participants |
| Placebo | Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event | Any Drug-Related AE | 5 Participants |
| Albiglutide 50 mg | Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event | Any AE | 9 Participants |
| Albiglutide 50 mg | Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event | Any SAE | 0 Participants |
| Albiglutide 50 mg | Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event | Any Drug-Related AE | 6 Participants |